Patterns of pharmacogenetic diversity in African populations: Role of ancient and recent history

Pharmacogenomics

Volumn 10, Issue 9, 2009, Pages 1413-1422

  Oliveira, Elisabete ^a   Pereira, Rui ^a,b   Amorim, António ^a   McLeod, Howard ^c   Prata, Maria João ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Admixture; African populations; Population based pharmacogenetics

Indexed keywords

CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; MULTIDRUG RESISTANCE PROTEIN 1;

AFRICAN AMERICAN; ARTICLE; ASIAN; CONTROLLED STUDY; DRUG METABOLISM; DRUG RESPONSE; ETHNIC DIFFERENCE; EUROPEAN AMERICAN; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SCREENING; GENETIC VARIABILITY; GEOGRAPHIC DISTRIBUTION; HISTORY; HUMAN; MOZAMBIQUE; PHARMACOGENETICS; POPULATION RESEARCH; PORTUGAL; RISK FACTOR; SAO TOME AND PRINCIPE; SINGLE NUCLEOTIDE POLYMORPHISM;

AFRICA; ALLELES; CLUSTER ANALYSIS; DEMOCRATIC REPUBLIC OF THE CONGO; DNA; GENETIC VARIATION; GENOTYPE; HISTORY, ANCIENT; HUMANS; MOZAMBIQUE; PHARMACOGENETICS; POLYMORPHISM, GENETIC; POPULATION; PORTUGAL; PRINCIPAL COMPONENT ANALYSIS;

EID: 70649104686     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.09.74     Document Type: Article

References (36)

1. Cheok MH, Lugthart S, Evans WE: Pharmacogenomics of acute leukemia. Annu. Rev. Pharmacol. Toxicol. 46, 317-353 (2006).
2. Sgaier SK, Jha P, Mony P et al.: Public health. Biobanks in developing countries: needs and feasibility. Science 318(5853), 1074-1075 (2007). (Pubitemid 350134883)
3. Matimba A, Oluka M, Ebeshi BU et al.: Establishment of a biobank and pharmacogenetics database of African populations. Eur. J. Hum. Genet. 16(7), 780-783 (2008). (Pubitemid 351865674)
4. Tishkoff SA, Verrelli B: Patterns of human genetic diversity: implications for human evolutionary history and disease. Annu. Rev. Genomics. Hum. Genet. 4, 293-340 (2003).
5. Oliveira E, Marsh S, van Booven DJ, Amorim A, Prata MJ, McLeod HL: Pharmacogenetically relevant polymorphisms in Portugal. Pharmacogenomics 8(7), 703-712 (2007).
6. Excoffier L, Laval G, Schneider S: Arlequin ver. 3.0: An integrated software package for population genetics data analysis. Evol. Bioinform. Online 1, 47-50 (2005).
7. Bertorelle G, Excoffier L: Inferring admixture proportions from molecular data. Mol. Biol. Evol. 15(10), 1298-1311 (1998). (Pubitemid 28452413)
8. Falush D, Stephens M, Pritchard JK: Inference of population structure using multilocus genotype data: dominant markers and null alleles. Mol. Ecol. Notes 7(4), 574-578 (2007). (Pubitemid 47035522)
9. Pritchard JK, Stephens M, Donnelly P: Inference of population structure using multilocus genotype data. Genetics 155(2), 945-959 (2000). □ Description of STRUCTURE software and its use to infer population structure using multilocus genotype data. (Pubitemid 30397141)
10. Takeuchi F, McGinnis R, Bourgeois S et al.: A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 5(3), E1000433 (2009)
11. Pearce CL, Near AM, van den Berg DJ et al.: Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium. Br. J. Cancer. 100(2), 412-420 (2009).
12. Gurwitz D, Zika E, Hopkins MM, Gaisser S, Ibarreta D: Pharmacogenetics in Europe: barriers and opportunities. Public Health Genomics 12(3), 134-141 (2009).
13. Wilson JF, Weale ME, Smith AC et al.: Population genetic structure of variable drug response. Nat. Genet. 29(3), 265-269 (2001).
14. Trovoada MJ, Pereira L, Gusmão L, Abade A, Amorim A, Prata MJ: Pattern of mtDNA variation in three populations from São Tomé e Príncipe. Ann. Hum. Genet. 68, 40-54 (2004). (Pubitemid 38219582)
15. Trovoada MJ, Tavares L, Gusmão L et al.: Dissecting the genetic history of São Tomé e Príncipe: a new window from Y-chromosome biallelic markers. Ann. Hum. Genet. 71, 77-85 (2007). (Pubitemid 44857684)
16. Beleza S, Gusmão L, Amorim A, Carracedo A, Salas A: The genetic legacy of western Bantu migrations. Hum. Genet. 117, 366-375 (2005). (Pubitemid 41194563)
17. Pereira L, Gusmão L, Alves C, Amorim A, Prata MJ: Bantu and European Y-lineages in sub-Saharan Africa. Ann. Hum. Genet. 66, 369-378 (2002). (Pubitemid 36004227)
18. Reiner AP, Ziv E, Lind DL, Nevergelt CM et al.: Population structure, admixture, and aging-related phenotypes in African American adults: The Cardiovascular Health Study. Am. J. Hum. Genet. 76, 463-477 (2005). (Pubitemid 40250526)
19. Suarez-Kurtz G, Pena S: Pharmacogenomics in the Americas: the impact of genetic admixture. Curr. Drug Targets 7(12), 1649-1658 (2006). □□ Review focusing on the impact of genetic admixture on pharmacogenomics. (Pubitemid 44873727)
20. Allabi A, Gala JL, Desager JP, Heusterspreute M, Horsmans Y: Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations. Br. J. Clin. Pharmacol. 56(6), 653-657 (2003) (Pubitemid 37491717)
21. Dorado P, Berecz R, Norberto MJ, Yasar A, Dahl ML, Llerena A: CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers. Eur. J. Clin. Pharmacol. 59(3), 221-225 (2003). (Pubitemid 37009744)
22. Yang J, Morin S, Verstuyft C et al.: Frequency of cytochrome P450 2C9 allelic variants in the Chinese and French populations. Fund. Clin. Pharmacol. 17(3), 373-376 (2003). (Pubitemid 36774173)
23. Kimura M, Ieiri I, Mamiya K, Urae A, Higuchi S: Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. Ther. Drug. Monit. 20(3), 243-247 (1998). (Pubitemid 28248841)
24. Zeigler-Johnson C, Walker A, Mancke B et al.: Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4. Hum. Hered. 54(1), 13-21 (2002). (Pubitemid 35404245)
25. van Schaik R, De Wildt S, van Iperen N, Uitterlinden A, van den Anker J, Lindemans J: CYP3A4-V polymorphism detection by PCR-restriction fragment length polymorphism analysis and its allelic frequency among 199 Dutch Caucasians. Clin. Chem. 46(11), 1834-1836 (2000).
26. Gervasini G, Vizcaino S, Gasiba C, Carrillo JA, Benitez J: Differences in CYP3A5*3 genotype distribution and combinations with other polymorphisms between Spaniards and other Caucasian populations. Ther. Drug Monit. 27(6), 819-821 (2005). (Pubitemid 44391742)
27. Naoe T, Takeyama K, Yokozawa T et al.: Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapy-related leukemia/myelodysplastic syndrome and de novo acute myeloid leukemia. Clin. Cancer Res. 6(10), 4091-4095 (2000). (Pubitemid 30807104)
28. Ball SE, Scatina J, Kao J et al.: Population distribution and effects on drug metabolism of a genetic variant in the 5′ promoter region of CYP3A4. Clin. Pharmacol. Ther. 66(3), 288-294 (1999). (Pubitemid 29451761)
29. Thompson E, Kuttab-Boulos H, Witonsky D, Yang L, Roe B, Di Rienzo A: CYP3A variation and the evolution of salt-sensitivity variants. Am. J. Hum. Genet. 75(6), 1059-1069 (2004). (Pubitemid 39534403)
30. Anglicheau D, Thervet E, Etienne I et al.: CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin. Pharmacol. Ther. 75(5), 422-433 (2004). (Pubitemid 38534563)
31. Allabi A, Horsmans Y, Issaoui B, Gala JL: Single nucleotide polymorphisms of ABCB1 (MDR1) gene and distinct haplotype profile in a West Black African population. Eur. J. Clin. Pharmacol. 61(2), 97-102 (2005). (Pubitemid 40674741)
32. Lotsch J, Skarke C, Geisslinger G: Simultaneous screening for three mutations in the ABCB1 gene. Genomics 82(5), 503-510 (2003). (Pubitemid 37239026)
33. Komoto C, Nakamura T, Sakaeda T et al.: MDR1 haplotype frequencies in Japanese and Caucasian, and in Japanese patients with colorectal cancer and esophageal cancer. Drug Metab. Pharmacokinet. 21(2), 126-132 (2006).
34. Tang K, Wong L, Lee E, Chong S, Lee C: Genomic evidence for recent positive selection at the human MDR1 gene locus. Hum. Mol. Genet. 13(8), 783-797 (2004). (Pubitemid 38515208)
35. Furuno T, Landi M, Ceroni M et al.: Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease. Pharmacogenetics 12(7), 529-534 (2002). (Pubitemid 35177082)
36. StatSoft Ltd www.statsoft.com